Glioma Stem Cells: Markers, Hallmarks and Therapeutic Targeting by Metformin

Pathology and Oncology Research

Volumn 20, Issue 4, 2014, Pages 789-797

  Najbauer, Joseph ^a   Kraljik, Nikola ^b   Németh, Péter ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Prevention and Outpatient Treatment of Addiction at the Institute of Public Health Osijek Baranja County   (Croatia)

Author keywords

Cancer stem cells; Glioma; Glioma stem cells; Metformin; Therapeutic targeting

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; BMI1 PROTEIN; BONE MORPHOGENETIC PROTEIN 4; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METFORMIN; NESTIN; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE B; SONIC HEDGEHOG PROTEIN; STAGE SPECIFIC EMBRYO ANTIGEN 1; STAT3 PROTEIN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG; WNT PROTEIN; ANTIDIABETIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER STEM CELL; CELL CYCLE ARREST; CELL VIABILITY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GLIOMA; GLIOMA STEM CELL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; DRUG EFFECTS; PATHOLOGY; PROGNOSIS;

GLIOMA; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASTIC STEM CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84919911736     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9837-z     Document Type: Review

References (55)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
3. Westphal M, Lamszus K (2011) The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 12:495–508
4. Gilbertson RJ, Rich JN (2007) Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7:733–736
5. Frank RT, Aboody KS, Najbauer J (2011) Strategies for enhancing antibody delivery to the brain. Biochim Biophys Acta 1816:191–198
6. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592
7. Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C et al (2011) Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 12:169–182
8. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurol 70:779–787
9. Visvader JE (2011) Cells of origin in cancer. Nature 469:314–322
10. Visvader JE, Lindeman GJ (2012) Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10:717–728
11. Nguyen LV, Vanner R, Dirks P, Eaves CJ (2012) Cancer stem cells: an evolving concept. Nat Rev Cancer 12:133–143
12. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ (2005) Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5:899–904
13. Filatova A, Acker T, Garvalov BK (2013) The cancer stem cell niche (s): the crosstalk between glioma stem cells and their microenvironment. Biochim Biophys Acta 1830:2496–2508
14. Binello E, Germano IM (2011) Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci 102:1958–1966
15. Facchino S, Abdouh M, Bernier G (2011) Brain cancer stem cells: current status on glioblastoma multiforme. Cancers (Basel) 3:1777–1797
16. Vescovi AL, Galli R, Reynolds BA (2006) Brain tumour stem cells. Nat Rev Cancer 6:425–436
17. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F et al (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13:1238–1241
18. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760
19. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284
20. Singh SK, Clarke ID, Hide T, Dirks PB (2004) Cancer stem cells in nervous system tumors. Oncogene 23:7267–7273
21. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401
22. Persano L, Rampazzo E, Basso G, Viola G (2013) Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem Pharmacol 85:612–622
23. Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:319–331
24. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA (2013) Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 24:469–480
25. Dunaif A (2008) Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome–a reappraisal. Nat Clin Pract Endocrinol Metab 4:272–283
26. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12:159–169
27. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M (2013) Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci 34:126–135
28. Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF (2012) Metformin and cancer therapy. Curr Opin Oncol 24:103–108
29. Pernicova I, Korbonits M (2014) Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10:143–156
30. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360–372
31. Witters LA (2001) The blooming of the French lilac. J Clin Invest 108:1105–1107
32. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M et al (2007) Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64:1290–1302
33. Shackelford DB, Shaw RJ (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9:563–575
34. Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S et al (2014) Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A 111:E435–444
35. Würth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A et al (2013) Metformin selectively affects human glioblastoma tumor-initiating cell viability: a role for metformin-induced inhibition of Akt. Cell Cycle 12:145–156
36. Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E et al (2011) FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells 29:1327–1337
37. Sato A, Sunayama J, Okada M, Watanabe E, Seino S et al (2012) Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med 1:811–824
38. Łabuzek K, Suchy D, Gabryel B, Bielecka A, Liber S et al (2010) Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 62:956–965
39. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305
40. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258
41. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302
42. Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK et al (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30:2844–2852
43. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507–7511
44. Hirsch HA, Iliopoulos D, Struhl K (2013) Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A 110:972–977
45. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G et al (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069–3075
46. Aboody KS, Najbauer J, Metz MZ, D’Apuzzo M, Gutova M et al (2013) Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med 5:184ra159
47. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G et al (2012) Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4:124ra127
48. Clarke J, Penas C, Pastori C, Komotar RJ, Bregy A et al (2013) Epigenetic pathways and glioblastoma treatment. Epigenetics 8:785–795
49. Najbauer J, Huszthy PC, Barish ME, Garcia E, Metz MZ et al (2012) Cellular host responses to gliomas. PLoS One 7:e35150
50. Dimov I, Tasić-Dimov D, Conić I, Stefanovic V (2011) Glioblastoma multiforme stem cells. Sci World J 11:930–958
51. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2012) The brain tumor microenvironment. Glia 60:502–514
52. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S et al (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153:139–152
53. Kourelis TV, Siegel RD (2012) Metformin and cancer: new applications for an old drug. Med Oncol 29:1314–1327
54. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J et al (2011) Metformin: multi-faceted protection against cancer. Oncotarget 2:896–917
55. Rattan R, Ali Fehmi R, Munkarah A (2012) Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol 2012:928127